1,531 results on '"Sperr, Wolfgang R"'
Search Results
2. 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
3. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study
4. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
5. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
6. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
7. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
8. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
9. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
10. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
11. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
12. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
13. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
14. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
15. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
16. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
17. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
18. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
19. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
20. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
21. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
22. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
23. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
24. A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells
25. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
26. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
27. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis
28. Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?
29. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia
30. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
31. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
32. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
33. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
34. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
35. Emicizumab for the treatment of acquired hemophilia A
36. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
37. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
38. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
39. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
40. Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis
41. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
42. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange
43. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
44. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
45. Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms
46. Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
47. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study
48. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
49. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
50. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.